Related Experiment Video
Updated: Nov 21, 2025

06:41
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
14.0K
Expansion of NEUROD2 phenotypes to include developmental delay without seizures
Emily K Mis1, Annalisa G Sega1, Rebecca H Signer2
1Pediatric Genomics Discovery Program, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
American Journal of Medical Genetics. Part A
|January 13, 2021
Summary
New research links Neuronal Differentiation Factor 2 (NEUROD2) gene variants to developmental delay without seizures. Functional tests confirmed a patient
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- De novo heterozygous variants in Neuronal Differentiation Factor 2 (NEUROD2) are linked to early-onset epileptic encephalopathy and developmental delay.
- NEUROD2 is a brain-specific transcription factor crucial for neuronal development.
Observation:
- A novel de novo heterozygous NEUROD2 missense variant, p.(Leu163Pro), was identified in an adolescent with developmental delay but no seizures.
- Functional testing in Xenopus laevis tadpoles indicated the patient's NEUROD2 variant exhibits minimal protein activity, suggesting a loss-of-function effect.
Findings:
- The patient's NEUROD2 variant demonstrated significantly reduced activity in vivo, supporting its role in developmental delay.
- A second rare NEUROD2 variant, p.(Ala235Thr), showed normal activity, highlighting the importance of specific variant pathogenicity.
Implications:
- NEUROD2 variants can cause developmental delay independently of early-onset seizures.
- In vivo functional assays are valuable tools to complement genetic data in determining variant pathogenicity.
- This study expands the phenotypic spectrum associated with NEUROD2 variants and emphasizes the utility of functional studies in genetic diagnostics.
More Related Videos
Related Concept Videos
Seizures: Classification
1.0K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.0K
Pleiotropy
42.2K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
42.2K
Epilepsy and Seizures: Overview
900
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
900
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
617
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
617

